Your Cart is Empty
GLP-1 medications have become one of the most talked-about developments in weight management. Drugs such as semaglutide and tirzepatide are changing how clinicians treat obesity, not because they offer a quick fix, but because they target some of the biological systems that help regulate appetite, fullness, blood sugar, and body weight.
For many years, people living with obesity were often told to simply “eat less and move more.” While nutrition and physical activity remain important, modern science now recognizes that body weight is influenced by a complex mix of hormones, genetics, metabolism, environment, medications, sleep, stress, and health conditions. GLP-1 drugs are part of this newer understanding.
What Are GLP-1 Drugs?
GLP-1 stands for glucagon-like peptide-1, a hormone naturally released by the gut after eating. It helps regulate blood sugar, slows how quickly food leaves the stomach, and sends signals to the brain that contribute to fullness.
GLP-1 medications mimic or enhance these effects. Some drugs act mainly on the GLP-1 pathway, while newer medications, such as tirzepatide, act on more than one gut-hormone pathway. The result for many people is reduced appetite, fewer food cravings, earlier fullness during meals, and lower overall calorie intake.
These medications were first developed for type 2 diabetes, but clinical trials showed that certain versions could also produce significant weight loss. Today, they are increasingly used as part of medical obesity treatment.
How Effective Are They for Weight Loss?
Clinical research has shown that GLP-1-based medications can produce meaningful weight loss for many patients, especially when used alongside nutrition, physical activity, and long-term medical support.
Semaglutide 2.4 mg, used for chronic weight management, has been shown in large clinical trials to help many participants lose a significant percentage of their body weight. Tirzepatide has also shown substantial weight-loss results in clinical studies and is now included in updated obesity pharmacotherapy guidelines.
In Canada, the 2025 obesity pharmacotherapy guideline update recognizes medications such as semaglutide and tirzepatide as evidence-based options for adults with obesity, or for adults with excess weight and weight-related health complications.
It is important, however, to understand that these medications do not work the same way for everyone. Some people lose a great deal of weight; others lose more modest amounts. Side effects, cost, access, medical history, and long-term tolerability all influence whether treatment is appropriate.
Benefits Beyond Weight Loss
One reason GLP-1 drugs have attracted so much medical attention is that their benefits may go beyond the number on the scale.
For people with type 2 diabetes, GLP-1 medications can improve blood sugar control and may reduce the need for other medications. Some GLP-1 drugs have also been shown to reduce the risk of major cardiovascular events, such as heart attack and stroke, in certain higher-risk patients.
The SELECT trial, a major study involving people with overweight or obesity and established cardiovascular disease but without diabetes, found that semaglutide reduced the risk of major cardiovascular events compared with placebo. This was an important finding because it suggested that some benefits may not be limited only to people with diabetes.
Research is also exploring potential benefits for fatty liver disease, kidney disease, sleep apnea, inflammation, and other obesity-related conditions. Some of these areas are promising, but not all are fully settled. As with any major medical advance, researchers are still learning which patients benefit most, which drugs work best for specific conditions, and how these medications should be used over the long term.
The Drawbacks and Side Effects
GLP-1 drugs are powerful medications, and they are not free of downsides.
The most common side effects are gastrointestinal. These may include nausea, vomiting, diarrhea, constipation, abdominal discomfort, reflux, or reduced appetite that feels unpleasant rather than helpful. For many people, these symptoms improve over time or with slower dose increases, but some people stop treatment because the side effects are too difficult.
More serious but less common concerns include gallbladder problems, pancreatitis, dehydration from vomiting or diarrhea, and possible worsening of certain gastrointestinal conditions. These medications also slow stomach emptying, which can matter before surgery or procedures requiring anesthesia.
Another very important concern is muscle loss. For ageing adults, this is a critically important issue to consider because older adults tend to suffer from muscle loss or sarcopenia. Muscle loss is closely associated with fragility in older age and has serious potential consequences like falls and bone fractures. Weight loss from any method can include both fat and lean tissue. This is why clinicians often recommend adequate protein intake and resistance exercise during treatment when taking GLP1s, especially for older adults.
They Are Usually Long-Term Medications
One of the biggest misconceptions about GLP-1 drugs is that they can be used briefly and then stopped once weight is lost.
Obesity is a chronic medical condition for many people. Studies show that when effective obesity medications are stopped, weight regain is common. This does not mean the treatment “failed.” It means the medication was helping regulate appetite and weight biology while it was being used.
For this reason, current obesity guidelines generally frame pharmacotherapy as long-term treatment when it is effective, tolerated, and medically appropriate.
Access and Cost Are Real Barriers
Even when these drugs are clinically appropriate, access can be difficult. In Canada, coverage varies by province, private insurance plan, diagnosis, and medication. Some people may be able to access treatment for diabetes but not for weight management alone. Others may face high out-of-pocket costs. Health Canada has recently approved a generic version of Ozempic making these drugs much more affordable than they used to be.
Supply shortages have also occurred, partly because demand has grown so quickly. This has raised ethical concerns about ensuring access for people with diabetes and other high-risk medical conditions.
Who Should Be Cautious?
GLP-1 drugs are not suitable for everyone. People with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 are generally advised not to use certain GLP-1 medications. Caution is also important for people with a history of pancreatitis, severe gastrointestinal disease, gallbladder disease, eating disorders, or those who are pregnant or planning pregnancy.
Anyone considering these medications should do so with a qualified healthcare provider who can review medical history, medications, risks, benefits, and appropriate monitoring.
A Balanced View
GLP-1 drugs are not magic, and they are not simply cosmetic weight-loss tools. They are serious medical treatments that can be life-changing for some people and inappropriate or poorly tolerated for others.
Their greatest value may be in helping shift the conversation around obesity. Rather than viewing weight as only a matter of willpower, these medications highlight the biological systems involved in appetite, metabolism, and long-term weight regulation.
Used carefully, GLP-1 medications can be an important part of obesity treatment, especially for people with weight-related health risks. But they work best as part of comprehensive care that includes nutrition, movement, sleep, mental health, medical monitoring, and realistic long-term planning.
